(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 June 2007 (07.06.2007)

PCT

(10) International Publication Number
WO 2007/062852 A3

(51) International Patent Classification:
C07K 16/18 (2006.01) *A61K 38/04* (2006.01)
C07K 14/47 (2006.01)

(21) International Application Number:
PCT/EP2006/011530

(22) International Filing Date:
30 November 2006 (30.11.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/740,866	30 November 2005 (30.11.2005)	US
60/779,171	3 March 2006 (03.03.2006)	US
60/787,361	30 March 2006 (30.03.2006)	US
60/842,400	5 September 2006 (05.09.2006)	US

(71) Applicants *(for all designated States except US)*: **ABBOTT LABORATORIES** [US/US]; 100 Abbott Park Road, Abbott Park, IL 60064 (US). **ABBOTT GMBH & CO. KG** [DE/DE]; Max-Plank-Ring 2, 65205 Wiesbaden (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BARGHORN, Stefan** [DE/DE]; Berliner Str. 30, 68161 Mannheim (DE). **EBERT, Ulrich** [DE/DE]; Königstuhlstr. 6, 68163 Mannheim (DE). **HILLEN, Heinz** [DE/DE]; Max-Planck-Str. 17, 67454 Hassloch (DE). **KELLER, Patrick** [DE/DE]; Bernhardstr. 30, 64291 Darmstadt (DE). **STRIEBINGER, Andreas** [DE/DE]; Ziegelofenweg 46A, 67346 Speyer (DE). **LABKOVSKY, Boris** [US/US]; 115 Union Road, P.O.Box 7, Wales, MA 01801 (US).

(74) Agent: **REITSTÖTTER-KINZEBACH**; Reitstötter, Kinzebach & Partner (GbR), Sternwartstrasse 4, 81679 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description*

(88) Date of publication of the international search report:
26 July 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES

(57) Abstract: Anti-Aβ globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-Aβ globulomer antibodies having a binding affinity to Aβ(20-42) globulomer that is greater than the binding affinity of the antibody to Aβ(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.

WO 2007/062852 A3